Edition:
United Kingdom

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

3.47USD
5:16pm GMT
Change (% chg)

$-0.04 (-1.14%)
Prev Close
$3.51
Open
$3.50
Day's High
$3.51
Day's Low
$3.47
Volume
4,389
Avg. Vol
23,669
52-wk High
$12.09
52-wk Low
$3.26

Select another date:

Fri, Dec 8 2017

BRIEF-Edgepoint Investment Group Reports 10.6 Pct Passive Stake In Novelion Therapeutics

* EDGEPOINT INVESTMENT GROUP INC REPORTS 10.6 PERCENT PASSIVE STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 30 - SEC FILING Source text : http://bit.ly/2yOFk6N Further company coverage:

BRIEF-Novelion Therapeutics Appoints Michael Price As CFO

* NOVELION THERAPEUTICS APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER

BRIEF-Novelion Therapeutics provides update on agreement between Aegerion Pharma and U.S. Department of Justice

* Novelion Therapeutics provides update on agreement between Aegerion Pharmaceuticals and U.S. Department of Justice

U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON A judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes of its marketing of a cholesterol drug, saying it was "not in the public interest."

UPDATE 1-U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON, Nov 20 A judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes of its marketing of a cholesterol drug, saying it was "not in the public interest."

U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON, Nov 20 A U.S. judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes into its marketing of a cholesterol drug, saying it was "not in the public interest."

U.S. JUDGE REJECTS PLEA DEAL WITH NOVELION THERAPEUTICS INC'S AEGERION PHARMACEUTICALS -COURT PAPERS

U.S. JUDGE REJECTS PLEA DEAL WITH NOVELION THERAPEUTICS INC'S AEGERION PHARMACEUTICALS -COURT PAPERS

BRIEF-Novelion Therapeutics says CEO resigns, posts Q3 results

* Novelion Therapeutics reports third quarter 2017 financial results and announces leadership change

U.S. submits revised plea deal with Novelion's Aegerion to court

BOSTON The U.S. Justice Department on Wednesday unveiled a revised a plea agreement with Aegerion Pharmaceuticals Inc that aimed to appease a federal judge who threatened to reject an earlier version that was part of a $36 million settlement.

U.S. submits revised plea deal with Novelion's Aegerion to court

BOSTON, Nov 1 The U.S. Justice Department on Wednesday unveiled a revised a plea agreement with Aegerion Pharmaceuticals Inc that aimed to appease a federal judge who threatened to reject an earlier version that was part of a $36 million settlement.

Select another date: